Novartis Entresto tablets achieve superior clinical benefits in PIONEER-HF trials

heart failure (heart failure) is a serious carry-on heart disease that causes weakness due to the inability of the heart to fully fill and drain bloodrecently, Novartis announced its Entresto tablets, which have achieved impressive and superior clinical benefits in the landmark PIONEER-HFtrial(in which it achieves impressive and superior clinical benefits compared to theof thedrug for heart failureEntresto was initially administered in hospital to treat patients with hypothermia fraction (HFrEF) who were hospitalized for acute indemnity heart failure (ADHF) eventsstudiesPIONEER-HF trials were designed to assess the effectiveness, tolerance, and safety of HFrEF patients admitted to hospital with stable conditions compared to Inapri (a type of ACEi) that were administered at the outset of hospitalization881 patients with an average age of 61 were enrolled in the trial, with a blood-shot score (EF) of 40%, and an amino end-pro b diuretic sodium peptide (NT-proBNP) of 1600 pg/mL or b-type sodium peptide (BNP) of 400 pg/mLNT-proBNP is an established biomarker used to assess the severity and prognosis of heart failurethe main endpoint of the trial was a change in NT-proBNP levels compared to the baseline during the fourth and eighth weeks of treatmentresults showed that Entresto reached the main end of the trial, with entresto group NT-proBNP levels reduced by 47%, while the Inapri group decreased by 25%, showing a statistical significant decrease of 29% compared to Inapri (95% CI: 0.63, 0.81; P 0.0001The trial observed that the NT-proBNP level had been significantly reduced in the Entresto group, a week after treatment